1alpha-hydroxyvitamin D3 in the long-term management of hypoparathyroidism and pseudohypoparathyroidism.
Normocalcaemia was restored and maintained in eleven hypoparathyroid and two pseudohypoparathyroid patients treated for up to 36 months with 1alpha-hydroxyvitamin D3. It was found to be a potent compound, maintenance doses ranging from 4 microgram weekly to 2 microgram daily. Supplementary oral calcium was used in acutely and profoundly hypocalcaemic patients but was given to only two patients as part of long-term therapy. Hypercalcaemic episodes occurring during treatment were of short duration and could be controlled by withdrawal of medication alone.
D000328:Adult; D000368:Aged; D002118:Calcium / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000009:adverse effects / Q000627:therapeutic use*; D006934:Hypercalcemia / Q000139:chemically induced; D007011:Hypoparathyroidism / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011547:Pseudohypoparathyroidism / Q000188:drug therapy*
D006887:Hydroxycholecalciferols; D002118:Calcium